Oruka Therapeutics, Inc.

Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Oruka Therapeutics to Participate in Multiple Upcoming Conferences

Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001

Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Oruka Therapeutics Announces New Board Member and Board Transition